Business Standard

Glenmark drug for mild Covid patients hits market, priced at Rs 103 a pill

FabiFlu is generic version of oral antiviral favipiravir; almost 80% patients are mildly sick, market potential for the oral drug is huge

pharma, medicines, drugs
Premium

India is adding over 12,000 cases of Covid-19 positive patients everyday

Sohini Das Mumbai
Oral antiviral drug favipiravir, which is used to treat patients with mild to moderate Covid-19 infection, will now be available in the Indian market under the brand name FabiFlu at Rs 103 per tablet. Glenmark Pharmaceuticals secured the drug regulator’s nod on Friday to manufacture and market the drug in India.  

The drug has shown promise in multiple global studies, with reduction in viral load, faster fever resolution, and faster clinical recovery. 

In India, the drug will be sold at retail chemist outlets as well as hospitals. This is an emergency use authorisation due to the pandemic situation prevalent in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in